

**Dr Margaret Christie**

Dr Margaret Christie obtained her PhD in Biological Chemistry from Imperial College London in 2003. Since then, she has been working in Research Services at The Institute of Cancer Research, London where she is responsible for managing The Institute's portfolio of European Commission contracts. Margaret has been involved in the AIDIT project since the submission of the successful proposal to the Commission in November 2004 and is on the management committee for the project. Margaret is delighted to have the opportunity to present a very brief introduction to European Funding at the AIDIT and IMPACT meeting in Szczecin.

**Assistant Professor Cezary Cybulski**

Assistant Professor Cezary Cybulski completed his medical training in 1996, followed by his PhD in pediatrics in 2001. He is currently an Assistant Professor in the Department of Genetics and Pathology at Pomeranian Academy of Medicine, Szczecin, Poland, where he has been working since 1992. He initiated studies on identification and registration of families with von Hippel-Lindau disease in Poland, and founded Polish VHL registry. He has been involved in studies on hereditary background of cancers, in particular of prostate cancer. He described NBS1 and CHEK2 mutations as prostate cancer predisposing alleles in Poland. Author/co-author of approximately 40 publications on hereditary cancer.

**Assistant Professor Ivanka Dimova**

Assistant Professor Ivanka Dimova MD PhD is Senior Assistant Professor at the Laboratory of Molecular Cytogenetics, Department of Medical Genetics, Medical University Sofia and University Hospital "Maichin Dom". Since completing her medical degree she has specialised in Medical Genetics, with the focus of her PhD being on the molecular cytogenetics of ovarian tumours. Prof Dimova's research interests include the genetics of ovarian tumors; oncogenes; tumor-suppressor genes and hereditary cancer; cDNA microarrays, biomarkers for screening, therapy and monitoring of common diseases; proteomic studies and in silico drug design.

**Ms Rebecca Doherty**

Rebecca Doherty is the Project Manager for the AIDIT project, which has received funding through the European Commission Framework 6 Programme to extend the IMPACT study into the associated candidate countries and new member states of the EU. Rebecca completed her BSc at the University of Melbourne in 1998, majoring in pathology and neurosciences. She subsequently trained as a genetic counsellor, becoming a Fellow of the Human Genetics Society of Australasia (Cancer Genetic Counselling) in 2004. As well as having worked in genetic counselling in both Australia and the UK, Rebecca has previous experience in project coordination and worked for a short time as a copyeditor at Nature Publishing Group.

**Professor Doug Easton**

Professor Doug Easton is a Cancer Research UK Principal Research Fellow and is the Director of the Cancer Research UK Genetic Epidemiology Unit based in Strangeways Research Laboratories, Cambridge. He is known internationally for his work on the penetrance of *BRCA1* and *BRCA2* gene mutations and risk modelling. His research interests include identification and characterisation of cancer predisposition genes, estimation of cancer risks in genetically predisposed individuals, evaluation of interactions between genetic and environmental risk factors and preventative strategies in at-risk individuals. He will provide statistical support for IMPACT.

**Dr Rosalind Eeles**

Dr Rosalind Eeles is Team Leader of the Translational Cancer Genetics team, Section of Cancer Genetics at The Institute of Cancer Research, Sutton, Surrey, UK. She is also the Head of The Cancer Genetics Unit at The Royal Marsden NHS Foundation Trust, London, UK. She is accredited in Clinical Oncology, has extensive experience in cancer genetics, and is a Fellow of the Royal Colleges of Physicians and Radiology (Clinical Oncology Faculty). She has over 160 original papers, many of which focus on genetic predisposition to prostate cancer.

Dr Eeles has two main programmes of research within the Section: prostate cancer predisposition genetics and clinical management of those with a genetic predisposition to breast and prostate cancer.

She has received long-term programme grant funding from Cancer Research UK over the last 10 years. She is the principal investigator of The IMPACT study, the largest international collaboration studying targeted screening in men for prostate cancer where there is a known genotype.

#### **Professor Gareth Evans**

Professor Gareth Evans is a clinical geneticist specialising in the management of men and women with cancer predisposition gene mutations. He has many publications in the field of cancer genetics and is Professor of Cancer Genetics in Manchester. He chaired the NICE committee on familial breast cancer and is currently Chairman of the Cancer Genetics Group, UK.

#### **Professor Christopher Foster**

Professor C. S. Foster is George Holt Professor of Pathology at the University of Liverpool. He is a specialist in the Cellular and Molecular Pathology of Human Cancers, particularly of the breast, prostate and bladder. Professor Foster received his BSc in Biochemistry at University College, London, in 1969 and qualified in Medicine at the Westminster Medical School in 1973. Thereafter, he combined specialist training in Diagnostic Surgical Pathology with doctoral studies into the biochemistry and cell biology of human breast cancer. In 1983, he received his PhD from the Institute of Cancer Research before continuing specialist training in the biochemistry and cell biology of cancer at the Children's Hospital of Philadelphia, USA, including a period of time spent at the National Institutes of Health, Washington, DC, completing an MD in 1987. On return to the United Kingdom, Professor Foster was appointed Senior Lecturer in Pathology at the Royal Postgraduate Medical School, London where he remained until his appointment in 1994 to the George Holt Chair of Pathology at the University of Liverpool. Here, he is in charge of an internationally-recognised research group concerned with the identification of genes responsible for promoting the invasive and metastatic phenotype of human cancers. In 2002, Professor Foster was awarded a DSc by an international panel for his contribution to understanding "The Cellular and Molecular Biology of the Metastatic Process". He is the author of several standard diagnostic pathology texts, the most recent being "Molecular Oncology of Prostate Cancer" (2007). For the past ten years, in addition to his academic work, Professor Foster has played a central advisory role, both in the North West and nationally to the Department of Health, in establishing Pathology Modernisation. He is Director of Workforce Planning for the Royal College of Pathologists and is Chairman of the National Committee on Modernising Pathology Careers (UK).

#### **Professor Bohdan Gorski**

Assistant Professor Bohdan Gorski completed his medical training in 1996, followed by his PhD in genetics in 1999. He is currently an Assistant Professor in the Department of Genetics and Pathology at Pomeranian Academy of Medicine, Szczecin, Poland. His recent research interests include familial cancer and familial hypercholesterolaemia.

#### **Assoc Prof Jacek Gronwald**

Assoc Prof Jacek Gronwald completed his medical training in 1991 and a PhD in oncology and genetics in 1997. Since that time he has specialised in obstetrics and gynaecology, as well as in clinical genetics. He has extensive international experience, having spent time as a visiting scientist in Germany, France and the USA. Assoc Prof Gronwald is currently based in the Department of Genetics and Pathology and the International Hereditary Cancer Center at Pomeranian Medical University, Szczecin, Poland.

#### **Professor Freddie Hamdy**

Professor Freddie C. Hamdy is the founding Chair of Urology and Director of the Division of Clinical Sciences (South) at the University of Sheffield Medical School, as well as Consultant Urological Surgeon at the Royal Hallamshire Hospital in Sheffield. He was appointed in January 1999 and developed the Academic Urology Unit, having spent 5 years as Consultant Senior Lecturer in Urology at the University of Newcastle. His main clinical interest is in the management of urological malignancies, particularly prostate and bladder cancer. His research activities encompass clinical, translational and basic science programmes on the biology of prostate and bladder cancer. He is Principal Investigator of a number of studies including the UK ProtecT (Prostate testing for cancer and Treatment) study of case-finding and randomised controlled trial of treatment in early prostate cancer. He has raised in excess of £18 million in research income over the past 10 years, and has published over 100 articles as peer-reviewed papers,

book chapters and reviews. He is member of a number of national and international committees, and chairs the Scientific Committee of the European Association of Urology.

#### **Dr John Harvey**

Dr John Harvey was originally employed in 1984 to set up the molecular genetics service in the existing Wessex Regional Cytogenetics Laboratory. In 1987 he was one of the small team that inaugurated the Clinical Molecular Genetics Society, later to become the British Society of Human Genetics. His lab has now grown substantially and offers a diagnostic service for the Wessex region covering more than 60 inherited disorders. Apart from developing a strong research base they were one of the two institutions awarded National Reference Lab Status in 1992. This has enabled them to objectively validate a range of novel diagnostic technologies feeding information and reports back to the UK Genetic Testing Network. Recently, as part of the National Genetics Reference Laboratories remit the laboratory has been setting up fast throughput systems to meet future demands.

#### **Professor Kari Hemminki**

Born 1947 in Finland, Professor Hemminki completed his MD at the University of Helsinki in 1973, a Ph.D in medical chemistry in 1973 and became docent in medical chemistry in 1975 at the University of Helsinki. He went on to work as a postdoctoral fellow at Johns Hopkins University, USA, from 1976-8, scientist from 1978-87, research professor 1987-92 and temporary chief physician 1993-95 at the Institute of Occupational Health, Helsinki, Finland. He was a Professor in Epidemiology with a special reference to chemical health risks (molecular epidemiology) at the Department of Biosciences, Karolinska Institute, Huddinge, Sweden 1989-2005 and was a Visiting Scientist at Frederick Cancer Research Facility, USA 1984-5, Massachusetts Institute of Technology, USA 1987, and the Institute of Public Health, University of Cambridge, UK 1999.

Since 2002 Professor Hemminki has worked as a Professor of molecular genetic epidemiology at the German Cancer Research Center (DKFZ) and the University of Heidelberg, Germany. He is the Chairman of Research Area C, Cancer Risk Factors and Prevention, DKFZ, and is Foreign Adjunct Professor of molecular genetic epidemiology, Karolinska Institute, Sweden, 2005-11.

#### **Dr Radka Kaneva**

Dr Radka Kaneva graduated from the Faculty of Biology, Sofia University, and obtained her PhD in Molecular Biology in 2000. She has been a research assistant at the National Oncology Centre and since 1992 a research associate and molecular biologist at the Laboratory of Molecular Pathology, currently the National Genetic Laboratory. Dr Kaneva specialised at the Department of Biochemistry, University of Oxford in 1993-94 and was awarded a Humboldt research fellowship at the Institute of Human Genetics, University of Bonn in 2001-03. The main research interests of Dr Kaneva are in the field of psychiatric and cancer genetics. She has been co-PI in large-scale international family and association studies of affective disorders and addiction, funded by the EC, NHMRC, and NIDA. Since 1998 she has participated as PI and co-PI in national projects on Hereditary Colorectal and Endometrial Cancer and was involved in the setting up of molecular genetic diagnostics of HNPCC at the National Genetic Laboratory. Since 2005 Dr Kaneva is the executive manager of the Molecular Medicine Center, Medical University of Sofia.

#### **Associate Professor Kathryn Kash**

Kathryn M. Kash, PhD, is Associate Professor of Psychiatry and Human Behavior at Thomas Jefferson University/Jefferson Medical College and Member of the Kimmel Cancer Center. She has been a practicing psychologist for 20 years and has spent her time helping young women with breast cancer cope with the disease and its impact on their lives. Dr. Kash's clinical practice is in the treatment of the emotional distress associated with cancer, primarily women with breast cancer, and helps women make informed decisions about genetic testing for cancer susceptibility, treatment for breast cancer, and strategies for the prevention of breast and ovarian cancer. Her current research interests are looking at how women make decisions about their health care and whether or not to undergo genetic counseling and testing, complementary approaches to breast cancer treatment, and determining patient preferences for enrolling in clinical trials. Dr. Kash has spent the last ten years involved in the training of psychiatric residents in various areas and establishing outcome measures to evaluate their ability to complete the six core competencies according to the Accreditation Council for Graduate Medical Education guidelines. She completed her graduate work in Psychology at the Graduate School and

University Center, City University of New York and completed a two-year fellowship in psycho-oncology at Memorial Sloan-Kettering Cancer Center.

### **Associate Prof Stoyan Lalchev**

Associate Prof Stoyan Lalchev graduated in Medicine in 1969 and subsequently specialised in Medical Genetics. He has worked in the Department of Medical Genetics, Sofia, Bulgaria, since 1970, where he is currently an Associated Professor. He obtained a PhD in population genetics and has practiced in Germany and France. Prof Lalchev is currently the President of the Bulgarian Society of Human Genetics and has previously acted as the National Counselor of Medical Genetics at the Ministry of Health.

Professor Lalchev's main scientific interests are in mutagenesis, biomonitoring, clinical genetics and immunodeficiency. He has more than 70 publications in national and international journals and is author and co-author of 4 monographs and 2 textbooks for students and physicians.

### **Professor Hans Lilja**

Professor Hans Lilja, MD, PhD (Member and Research Clinical Chemist, Department of Clinical Laboratories, Clinical Chemistry Services, and Member of the Departments of Urology and Medicine, MSKCC) joined MSKCC in 2003 and currently directs the tumor marker laboratory. The discoverer of "free" PSA and other prostate related proteins, Dr. Lilja is interested in circulating tumor markers that predict the development and progression of prostate cancer by many years, and in the possibility that these related enzymes play a key role in the pathogenesis of prostate cancer. Dr. Lilja and his team researches early disease-specific, protease-related patterns of prostate cancer to develop early risk-group stratification, discriminate clinically significant from insignificant prostate cancer, identify non-curable disease, and monitor therapeutic efficacy. Additionally, Dr. Lilja is investigating novel principles of chemoprevention, responsible for blocking the activation of local growth stimulatory factors as a result of the release of latent and active forms of prostatic kallikreins and related proteases.

### **Professor Jan Lubinski**

Prof Jan Lubinski has been the national consultant for clinical genetics in Poland since 1998. He is the Head of International Hereditary Cancer Center organized in Poland in 1992. The most important divisions of this center are a network of cancer genetic outpatient clinics covering almost entire country and a cancer bio-bank with biological samples and clinical data from 135,000 cancer cases and appropriate controls, including registries of thousands of mutation carriers such as a registry of 3,500 *BRCA1* carriers.

Prof Lubinski is an author of around 200 papers on clinical and molecular genetics of cancers and author and coordinator of several EU-funded projects. He is an editor of a journal published under auspices of UICC – Hereditary Cancer in Clinical Practice. In 2005 he was awarded the title of Doctor Honoris Causa of Riga Stradins University, Riga, Latvia.

### **Dr Lovise Mæhle**

Dr Lovise Mæhle works as a consultant in medical cancer genetics at the Norwegian Radium Hospital in Oslo, Norway. She completed a PhD in 1999 on Nickel carcinogenesis and effects of omega 3 fatty acids on cancer cell growth. She was a visiting researcher in Ros Eeles' group at the Royal Marsden Hospital and The Institute of Cancer research for 3 months in 2004. Dr Mæhle's main research interest is hereditary prostate cancer.

### **Dr Esra Manguoglu**

Dr Esra Manguoglu completed a B.Sc. degree from the Department of Biological Sciences, Middle East Technical University, in Ankara Turkey in 1997. She then completed an M.Sc. Program in Medical Biology at Akdeniz University, Antalya, Turkey in 1999. In 2004 she received her Ph.D. degree in Medical Genetics in the same University. Dr Manguoglu's PhD thesis was about the role of *BRCA* gene germline mutations in patients with inherited breast and ovarian cancer. During her Ph.D. program she spent one year in the Oncogenetic Unit of Sheba Medical Center in Israel for collaborative work under the supervision of Prof. Eitan Friedman. Dr Manguoglu has been a member of the Turkish Society of Medical Genetics since 1999. She currently works as a post-doctoral fellow in the department of Medical Biology and Genetics, Faculty of Medicine, Akdeniz University, Antalya, Turkey. Her current research interests

are genetic predisposition to the inherited cancers, drug resistance in epilepsy and molecular genetics of inherited diseases.

### **Prof Gert Matthijs**

Professor Gert Matthijs, PhD (1963) is the Head of the Laboratory for Molecular Diagnostics at the Center for Human Genetics in Leuven, Belgium. He is a molecular geneticist, involved in the diagnostics of inherited diseases since 1994, and professor at the University of Leuven since 2003. His major research interest is in Congenital Disorders of Glycosylation (CDG), a group of rare inborn errors of metabolism. He is also the deputy-coordinator of EuroGentest, a network of excellence (NoE) for development, harmonization, validation and standardization of genetic testing in Europe, funded by the European Commission. At the national level, he has been a thriving force for a revision of the reimbursement system for genetic tests. He chairs the Patenting and Licensing Committee of the European Society of Human Genetics, and is also actively involved in the European opposition against the BRCA patents.

### **Dr Gillian Mitchell**

Dr Gillian Mitchell is the Director of the Familial Cancer Centre at the Peter MacCallum Cancer Centre in Melbourne, Australia. She is a Clinical Oncologist with a specialist interest in the identification and management of individuals with a familial predisposition to cancer.

Gillian originated from the UK and trained as a Clinical Oncologist at the Royal Marsden Hospital, London, UK. She completed a research degree at the Institute of Cancer Research, London, in the clinical aspects of the identification and breast cancer risk assessment of female *BRCA1/2* mutation carriers under the supervision of Dr Ros Eeles.

Gillian now heads a Familial Cancer Centre and continues to have an active research role as the chairman of the translational subcommittee of kConFab, the Principal Investigator (PI) of the Australian arm of the IMPACT study, the PI of the Australian arm of Astra Zeneca's PARPi studies in female *BRCA1/2* mutation-carriers with advanced breast or ovarian cancer as well as developing a national breast MRI screening service for women with a familial breast cancer risk

### **Dr Anita Mitra**

Dr Anita Mitra is a Clinical Research Fellow at the Institute of Cancer Research, UK coordinating the international IMPACT study, and is currently working towards a PhD. She is accredited in Clinical Oncology and works at the Royal Marsden NHS Foundation Trust in the departments of Uro-Oncology and Cancer Genetics. She has over 6 years' experience in oncology and is developing her special interest in urological malignancies and cancer genetics.

### **Professor Francisc Mixich**

Professor Francisc Mixich is University Professor, Head of the Department of Molecular and Cellular Biology of the Faculty of Medicine at the University of Medicine and Pharmacy of Craiova and Coordinator of the Molecular Diagnostics and DNA Typing Laboratory at the same university. In 1992 Francisc Mixich obtained the title of Doctor in Biological Sciences at University of Bucharest. He is a member of many national and international scientific societies and has been involved in several European-financed research projects.

### **Dr Vlad Alexandru Mixich**

Dr Vlad Alexandru Mixich obtained a degree in medicine at the University of Medicine and Pharmacy "Victor Babes" of Timisoara and from November 2005 is a PhD student at the University of Medicine and Pharmacy of Craiova. He published several papers in national and international scientific journals, focusing on the pharmacogenetics field. In September 2006 he obtained a diploma in psychotherapy at the Institute of Psychiatry, London.

### **Miss Sarah Morgan**

Sarah Morgan is a website administrator employed at The Institute of Cancer Research to coordinate the development of a website for IMPACT. A trained Science Communicator, Miss Morgan is responsible for

developing the content of the IMPACT website, and liaising with external design and translation companies to coordinate the launch of the IMPACT website.

#### **Dr Jan C. Oosterwijk**

Dr Jan Oosterwijk studied medicine at Free University in Amsterdam, specialised in Clinical Genetics at Utrecht University Hospital and worked as a consultant in Clinical Genetics at the Leiden University, where he defended his PhD thesis on the detection of fetal cells in maternal blood in 1998. He left for Groningen University to become Senior Consultant in Clinical Genetics and Consultant in Clinical Oncogenetics of the Comprehensive Cancer Centre North Netherlands. As of 2006 he is head of the Clinical Genetics section and head of Clinical Genetics training programme in Groningen.

Dr Oosterwijk is a member of the Dutch Working party on Clinical Oncogenetics and of the UK Cancer Genetics Study Group. He is vice-chairman of the Dutch Clinical Genetics Education Board and a member of the Board of the Royal Dutch College of Physicians' Specialists Registration Committee. He has (co-) authored over 100 publications on congenital/hereditary syndromes, prenatal diagnosis, mental retardation, ethics, hereditary cancer and genetic counselling.

#### **Dr Ana Osorio Cabrero**

Dr Ana Osorio Cabrero joined the Department of Genetics of Fundación Jiménez Díaz in Madrid in 1995, completing her PhD in 1999. Her doctoral research focused on the molecular characterization of the then recently isolated breast cancer susceptibility genes, *BRCA1* and *BRCA2*, in the Spanish Population. Dr Osorio moved to the Spanish National Cancer Centre in Madrid as the Human Genetics Group was established in 2000 inside the Molecular Pathology Programme. Dr Osorio and colleagues collaborate on many national and international projects including the Breast Cancer Linkage Consortium, the CIMBA consortium for the identification of genetic modifiers of *BRCA1* and *BRCA2*, and the International *BRCA1* and *BRCA2* Carrier Cohort Study. Dr Osorio herself runs two projects: an analysis of hereditary breast tumours using cDNA microarrays and a search for genetic modifiers of *BRCA1* and *BRCA2* penetrance. In 2001 the team established the Spanish Consortium for the study of Breast Cancer Genetics and has published several collaborative papers in this subject, mainly focused on translational research.

#### **Dr Gad Rennert**

Dr Gad Rennert, M.D., Ph.D. is the Chairman of the Department of Community Medicine and Epidemiology at Carmel Medical Center and B. Rappaport Faculty of Medicine-Technion, in Haifa, Israel, is the Director of the CHS National Israeli Cancer Control Center and is heading the national breast and colorectal cancer screening programs of Israel. Dr. Rennert is an epidemiologist trained at the University of North Carolina with more than fifteen years of experience designing, directing, and supervising the fieldwork of epidemiological studies. Dr. Rennert is running the National Familial Cancer Consultation Service of the largest health provider in Israel. This service has already evaluated more than 3500 families suspected of familial cancer and is caring for more than 450 *BRCA*-positive families. He has numerous publications in molecular cancer epidemiology including *BRCA*-gene-related epidemiology.

#### **Dr Monique Roobol**

Dr Monique Roobol was born on October 22, 1961 in Rotterdam, the Netherlands. From 1985 – 1991 she worked as a molecular biologic technician at the department of Immunology of the Erasmus Medical Center. The topic of her research was the cellular and molecular biologic characteristics of mesothelioma. In 1991 she started working as data manager of the Dutch part of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at the department of Urology of the Erasmus Medical Centre. In 1998 she wrote her first publication and in 2002 she graduated for her masters degree in Epidemiology. On December 21, 2005 she defended her thesis "Prostate cancer screening: tests and algorithms" successfully and obtained her PhD. So far, she has published 10 papers of which she is the first author and 32 papers of which she is co-author. At present she is still working as study coordinator at the department of Urology.

#### **Dr Asher Salmon**

Dr Asher Salmon received his MD degree from the Faculty of Medicine, The Technion, Israel Institute of Technology, Haifa. He studied for a PhD in Molecular Biology at the Hebrew University, Jerusalem. He did his residency in Clinical Oncology at the Sharet Institute of Oncology, Hadassah University Medical

Center and then as a Clinical Research Fellow at the Royal Marsden Hospital and The Institute of Cancer Research, London, U.K. He is now a consultant in Clinical Oncology and the acting manager of the outpatient clinic of the Sharrett Institute of Oncology, Hadassah University Medical Center.

### **Professor Rodney Scott**

Professor Rodney J. Scott obtained his PhD from the University of Western Australia in 1987 in cell and molecular biology. Thereafter Professor Scott undertook two post-doctoral positions, the first in Western Australia and the second at the University of Texas Health Science Centre in Houston. In 1990 Professor Scott was appointed to the position of Research Group Leader at the Division of Human Genetics, University Clinics Basel, Switzerland. During this time he was invited to participate in international collaborations on familial cancer. In 1997 Professor Scott took up his appointment with the Hunter Area Pathology Service as Director of Cytogenetics and Molecular Genetics and became the Head of the Discipline of Medical Genetics at the University of Newcastle at the end of 1999. In 1999 Professor Scott was invited to become a visiting Professor at the Pomeranian Medical University in Poland. Professor Scott is currently an advisor to the NSW Cancer Council's Familial Bowel Cancer Registry and a member of the NSW Department of Health's Genetic Services Advisory Committee, DNA working party and chair of the Cancer Genetics working party. He is also chair of the Board of Censors for Molecular Genetics, Human genetics Society of Australasia.

### **Dr Christi J van Asperen**

Dr Christi van Asperen has worked in the field of Clinical Genetics since 1991 and in 1995 was posted to the Netherlands Cancer Institute to start up the Familial Cancer Clinic. In 1996 she moved to the Department of Clinical Genetics at the Leiden University Medical Center, and since 2001 has been Head of the Genetic Counselling section. In 2004 she completed a PhD thesis on risk estimation in familial breast cancer. She is also a member of the Working Party at the Dutch Institute for Healthcare Improvements, CBO, developing an evidence-based guideline for women at high risk of breast cancer. She is a member of several national and international organisations including CRISCOM (a research initiative with the aim of comparing risk communication in cancer genetics across Europe), ICG-FBOC (an international collaborative group on clinical research in familial breast cancer) and the National Working Party in Oncogenetics (WKO) for which she is the first author of the WKO national guideline on the Medical Management of hereditary breast and ovarian cancer.

### **Dr Jane Warwick**

Dr Jane Warwick is a senior statistician in the Cancer Screening and Aetiology Group of the Cancer Research UK Department of Mathematics, Epidemiology and Statistics based at the Wolfson Institute of Preventive Medicine, Queen Mary's College, University of London. Her primary research interest is in breast cancer screening and breast cancer prevention; specifically, the evaluation of established population-based mammographic screening programmes (service screening) and the potential usefulness of changes in mammographic breast density as an earlier indicator of efficacy in chemoprevention studies. She also maintains a personal interest in the management of ovarian and other gynaecological cancers.